This report examines the business case and value of engagement for pharmaceutical companies in developing countries. It provides case examples of the strategies employed by several successful pharmaceutical companies and outlines three business strategies that large pharmaceutical companies can adopt to increase development impact: 'creating inclusive business models', 'capacity building initiatives', and 'rule shaping activities'.